Journal of Alzheimer's Disease最新文献_第4页

Trends of antipsychotic prescribing for people with dementia in Spain. 西班牙痴呆症患者抗精神病药物处方趋势。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-17 DOI: 10.1177/13872877251359682

Antonio Sánchez-Soblechero, Miguel Gil, José Manuel Rojo, Ruben Muñiz, Mª Canto de Hoyos-Alonso, Javier Olazarán

{"title":"Trends of antipsychotic prescribing for people with dementia in Spain.","authors":"Antonio Sánchez-Soblechero, Miguel Gil, José Manuel Rojo, Ruben Muñiz, Mª Canto de Hoyos-Alonso, Javier Olazarán","doi":"10.1177/13872877251359682","DOIUrl":"https://doi.org/10.1177/13872877251359682","url":null,"abstract":"BackgroundAntipsychotic medications are frequently prescribed in people with dementia (PwD), despite concern regarding risk-benefit balance.ObjectiveTo describe the evolution of antipsychotic prescribing for PwD in Spain, with special interest in the effect of administration regulatory warnings (2004 and 2008).MethodsLongitudinal retrospective study using the national Spanish Database for Pharmacoepidemiological Research in Primary Care (BIFAP). We included patients with incident dementia during the study period (January 1, 2002 to December 31, 2018) and excluded those with major psychiatric conditions, mental retardation, or previous use of antipsychotics. Paper-based and electronic prescriptions of antipsychotics were collected. Annual prevalence of prescribing was obtained for single medications and antipsychotic group. All calculations were conducted for the total sample and stratified by sex. The results were compared with those of other countries.ResultsAntipsychotic prescribing doubled during the study period, raising from 12.6% (2002) to 23.8% (2018). A mild decrease of prescribing was observed from 2004 to 2007, followed by steady increase from 2007 on. This increase was due to atypical antipsychotic use, specifically quetiapine, which grew from 0.2% (2002) to 16.4% (2018) and was more frequently utilized in men. Spain prevalence of antipsychotics doubled the UK's.ConclusionsBetter designed warnings appear as a key means to rationalize use of antipsychotics in Spain and other countries, ideally as part of national dementia strategies. Dearly needed non-pharmacological approaches for comprehensive treatment of neuropsychiatric symptoms could be generalized as a first step through nursing home and day care networks. Quetiapine requires the agencies' urgent attention.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251359682"},"PeriodicalIF":3.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic syndrome and dementia: Independent risk factors or a unified pathway? 代谢综合征和痴呆：独立的危险因素还是统一的途径？

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-17 DOI: 10.1177/13872877251359635

Fausto Roveta, Silvia Boschi, Elisa Rubino, Innocenzo Rainero

引用次数: 0

The gap between amyloid pathology and cognition. 淀粉样蛋白病理学和认知之间的差距。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-15 DOI: 10.1177/13872877251359637

V Alexandra Moser

引用次数: 0

Cohort profile: China healthy aging cohort study (China-Aging). 队列简介：中国健康老龄化队列研究（China- aging）。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-15 DOI: 10.1177/13872877251360028

Jie Chang, Yue Wu, Yiwei Zhao, Xue Gao, Yiwen Xing, Zhibin Wang, Qi Qin, Wenqing Ni, Yangwei Ying, Xiaoyan Liu, Lumin Leng, Hong Zhou, Lina Ma, Yansu Guo, Guoping Peng, Yong You, Jindong Ding Petersen, Jian Xu, Yi Tang

{"title":"Cohort profile: China healthy aging cohort study (China-Aging).","authors":"Jie Chang, Yue Wu, Yiwei Zhao, Xue Gao, Yiwen Xing, Zhibin Wang, Qi Qin, Wenqing Ni, Yangwei Ying, Xiaoyan Liu, Lumin Leng, Hong Zhou, Lina Ma, Yansu Guo, Guoping Peng, Yong You, Jindong Ding Petersen, Jian Xu, Yi Tang","doi":"10.1177/13872877251360028","DOIUrl":"https://doi.org/10.1177/13872877251360028","url":null,"abstract":"BackgroundAs China undergoes a demographic transition towards an aging society, the prevalence and incidence of age-related disabilities, Alzheimer's disease, and various geriatric syndromes are steadily rising.ObjectiveThe China Healthy Aging Cohort Study (China-Aging) aims to investigate the prevalence and associated risk factors of disability and cognitive impairment, and to develop predictive models for these conditions by combining traditional risk factors with artificial intelligence-derived metrics (such as gait, speech, vision, etc.).MethodsThe China-Aging cohort consists of community-dwelling participants aged 60 years and older from Beijing, Hangzhou, Shenzhen, and Haikou. The baseline recruitment was from May 16, 2022 to March 19, 2025, with study participants primarily from urban areas. Follow-up assessment of the cohort will occur every 1-3 years from the baseline.ResultsAmong 6283 participants who completed the baseline evaluation (mean age 70.6 years, SD 6.3), 3775 (60.1%) were women. The overall prevalence of disability, cognitive impairment, frailty, depression, and sarcopenia were 17.8%, 18.5%, 5.9%, 7.1%, and 5.7%, respectively. The prevalence of disability in the Beijing cohort was higher than in other cohorts (Beijing: 35.6%, Hangzhou: 6.5%, Shenzhen: 6.8%, Haikou: 10.9%) and the prevalence of cognitive impairment in the Haikou cohort was higher than in other cohorts (Beijing: 9.5%, Hangzhou: 7.9%, Shenzhen: 16.2%, Haikou: 45.5%).ConclusionsThe prevalence of disability and cognitive impairment is relatively high, and notable regional difference exists in China. China-Aging cohort provides crucial evidence for the precise prevention and management of disability, cognitive impairment, and other geriatric syndromes in promoting active and healthy aging.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251360028"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alzheimer's disease classification using mutual information generated graph convolutional network for functional MRI. 基于互信息生成图卷积网络的功能MRI阿尔茨海默病分类。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-15 DOI: 10.1177/13872877251350306

Yinghua Fu, Li Jiang, John Detre, Ze Wang

{"title":"Alzheimer's disease classification using mutual information generated graph convolutional network for functional MRI.","authors":"Yinghua Fu, Li Jiang, John Detre, Ze Wang","doi":"10.1177/13872877251350306","DOIUrl":"https://doi.org/10.1177/13872877251350306","url":null,"abstract":"BackgroundHigh-order cognitive functions depend on collaborative actions and information exchange between multiple brain regions. These inter-regional interactions can be characterized by mutual information (MI). Alzheimer's disease (AD) is known to affect many high-order cognitive functions, suggesting an alteration to inter-regional MI, which remains unstudied.ObjectiveTo examine whether inter-regional MI can effectively distinguish different stages of AD from normal control (NC) through a connectome-based graph convolutional network (GCN).MethodsMI was calculated between the mean time series of each pair of brain regions, forming the connectome which was input to a multi-level connectome based GCN (MLC-GCN) to predict the different stages of AD and NC. The spatio-temporal feature extraction in MLC-GCN was used to capture multi-level functional connectivity patterns generating connectomes. The GCN predictor learns and optimizes graph representations at each level, concatenating the representations for final classification. We validated our model on 552 subjects from ADNI and OASIS3. The MI-based model was compared to models with several different connectomes defined by Kullback-Leibler divergence, cross-entropy, cross-sample entropy, and correlation coefficient. Model performance was evaluated using 5-fold cross-validation.ResultsThe MI-based connectome achieved the highest prediction performance for both ADNI2 and OASIS3 where it's accuracy/Area Under the Curve/F1 were 87.72%/0.96/0.88 and 84.11%/0.96/0.91 respectively. Model visualization revealed that prominent MI features located in temporal, prefrontal, and parietal cortices.ConclusionsMI-based connectomes can reliably differentiate NC, mild cognitive impairment and AD. Compared to other four measures, MI demonstrated the best performance. The model should be further tested with other independent datasets.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251350306"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Alzheimer's association workgroup criteria underestimate syndromes in Alzheimer's disease definition. 新的阿尔茨海默病协会工作组标准低估了阿尔茨海默病定义中的综合征。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-15 DOI: 10.1177/13872877251359642

Carlo Abbate, Alessia Gallucci

引用次数: 0

Brain amyloid-β deposition, severity of subjective cognitive decline and gait speed in cognitively unimpaired oldest-old. 脑淀粉样蛋白-β沉积，认知功能未受损的老年人主观认知衰退的严重程度和步态速度。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-15 DOI: 10.1177/13872877251359638

Neelesh K Nadkarni, Subashan Perera, Beth E Snitz, Brian J Lopresti, Marissa A Gogniat, Victor L Villemagne, Oscar L Lopez

{"title":"Brain amyloid-β deposition, severity of subjective cognitive decline and gait speed in cognitively unimpaired oldest-old.","authors":"Neelesh K Nadkarni, Subashan Perera, Beth E Snitz, Brian J Lopresti, Marissa A Gogniat, Victor L Villemagne, Oscar L Lopez","doi":"10.1177/13872877251359638","DOIUrl":"https://doi.org/10.1177/13872877251359638","url":null,"abstract":"BackgroundGait speed slows prior to cognitive decline in clinical Alzheimer's disease (AD), and is associated with cognitive performance and biomarkers of amyloid-β (Aβ) pathology in cognitively unimpaired (CU) older adults. However, the influence of subjective cognitive decline (SCD) severity on the association between Aβ and gait speed is not known.ObjectiveWe examined the relationship among gait speed, SCD severity and Aβ deposition in CU older adults.MethodsGait speed was measured over 15-feet. Aβ deposition was quantified using Pittsburgh-B (PiB) PET, expressed in Centiloid units (CL). Severity of SCD was quantified on the Memory Functioning Questionnaire (MFQ) on measures of seriousness and frequency of forgetting, mnemonic usage and retrospective functioning. We fitted a series of linear models with gait speed as the dependent variable; and each dichotomized sub-scale of the MFQ and Aβ as independent variables, adjusting for depression, white matter hyperintensity volume and executive function.ResultsIn 58 CU individuals (mean age 85, 35% female), mean gait speed was 0.91 m/s and Aβ deposition was 36 CL. The relationship between slower gait and greater Aβ deposition showed a stronger association in those with more frequent mnemonic use (r = -0.36, p = 0.05) and with greater seriousness of forgetting (r = -0.33, p = 0.08) compared to those with lesser severity of subjective cognitive concerns (r = 0.02, p = 0.9 and r = -0.08, p = 0.7 respectively).ConclusionsThe findings indicate that in those with greater severity of SCD, association between slower gait and greater Aβ deposition is stronger, warranting longitudinal assessments of SCD severity and gait changes in preclinical AD.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251359638"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring causal gut-brain axes in Alzheimer's disease using mediation Mendelian randomization analysis. 利用中介孟德尔随机化分析探索阿尔茨海默病的因果肠-脑轴。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-15 DOI: 10.1177/13872877251360004

Lili Ge, Lin Zhu, Chen Su, Zhi Jin

{"title":"Exploring causal gut-brain axes in Alzheimer's disease using mediation Mendelian randomization analysis.","authors":"Lili Ge, Lin Zhu, Chen Su, Zhi Jin","doi":"10.1177/13872877251360004","DOIUrl":"https://doi.org/10.1177/13872877251360004","url":null,"abstract":"BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative condition with unclear etiology. Recent studies suggest gut microbiota may be involved in AD pathogenesis through imbalances that increase intestinal permeability, affect blood-brain barrier function, and promote neuroinflammation. However, observational studies are susceptible to confounding biases and reverse causality.ObjectiveThis study aimed to explore causal relationships between gut microbiota, brain imaging-derived phenotypes (IDPs), and AD using mediation Mendelian randomization analysis to identify specific gut-brain axes involved in AD mechanisms.MethodsWe conducted a three-phase Mendelian randomization analysis using large-scale genome-wide association study (GWAS) data. Phase 1 analyzed causal effects of 412 gut microbiota on AD. Phase 2 examined causal effects of 920 IDPs on AD. Phase 3 performed mediation analysis to understand the role of IDPs in the gut microbiota-AD pathway. Data sources included Dutch population study (7738 individuals), MiBioGen consortium (18,340 individuals), UK Biobank brain imaging (8428 samples), and AD GWAS dataset (487,511 participants). Inverse variance weighted method was the primary analysis approach.ResultsWe identified 12 gut microbiota metabolic pathways and 32 gut microbiota species causally related to AD, plus 29 IDPs with potential causal relationships to AD. Mediation analysis revealed four distinct gut-brain axes: genus Butyrivibrio-brain stem-AD, genus Lachnospiraceae-brain stem-AD, PEPTIDOGLYCANSYN pathway-L1 External capsule Left-AD, and TCA cycle pathway-L1 External capsule Left-AD.ConclusionsThis study identified four specific gut microbiota-brain structure axes causally involved in AD mechanisms, providing novel insights for understanding the gut-brain axis role in AD pathogenesis and potential therapeutic targets.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251360004"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel traditional Chinese medicine formula restores sleep and cognitive function in APP/PS1 mice by targeting glycolytic pathways and neuroinflammatory responses. 一种新的中药配方通过靶向糖酵解途径和神经炎症反应来恢复APP/PS1小鼠的睡眠和认知功能。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-13 DOI: 10.1177/13872877251355596

Jiani Zhang, Chunxiang Wang, Kexin Chang, Tiantian Peng, Chengbang Liang, Junshi Cheng, Yu Shi, Xu Wang, Zhaoyang Wang, Yan Tan, Qian Hua

{"title":"A novel traditional Chinese medicine formula restores sleep and cognitive function in APP/PS1 mice by targeting glycolytic pathways and neuroinflammatory responses.","authors":"Jiani Zhang, Chunxiang Wang, Kexin Chang, Tiantian Peng, Chengbang Liang, Junshi Cheng, Yu Shi, Xu Wang, Zhaoyang Wang, Yan Tan, Qian Hua","doi":"10.1177/13872877251355596","DOIUrl":"https://doi.org/10.1177/13872877251355596","url":null,"abstract":"BackgroundAlzheimer's disease (AD) is recognized as a multifactorial neurodegenerative disorder involving numerous cellular and molecular processes, such as sleep disturbance, imbalance in brain glucose metabolism and neuroinflammation; these dysregulations typically precede the onset of symptoms. Hence, the results of mono-target therapy after AD diagnosis are in many cases unsatisfactory.ObjectiveTraditional Chinese medicine (TCM) presents significant potential for treating AD. Sleep disorders are one of the early symptoms of AD; however, there is no effective solution to sleep disorders caused by AD. Some TCMs have been shown to treat sleep disorders by regulating energy metabolism or improving neuroinflammation. This study aims to investigate if XX-F administrated in advance could alleviate AD by improving sleep quality and neuroinflammation.MethodsMice were given Xiexintongfu formula (XX-F) intragastrically for three months. Morris water maze and pentobarbital-induced sleep test were performed to evaluate cognition and sleep. Determine changes in energy metabolism related to glycolysis through western blot and specific assay kits. Using immunofluorescence and western blot to detect neuroinflammation.ResultsShortened sleep duration and cognitive impairment were observed in 6-month-old APP/PS1 mice. XX-F significantly prolonged sleep duration and rescued cognition. In addition, XX-F reduced the number of amyloid-β (Aβ) plaques and ameliorated neuroinflammation, and inhibited glycolysis by reducing pyruvate kinase M2 (PKM2) and lactate levels while rescuing adenosine triphosphate (ATP) deficiency.ConclusionsWe demonstrate that XX-F can improve sleep and cognition of AD mice by regulating energy metabolism and reducing neuroinflammation. This is a potential treatment method for AD and requires further in-depth research.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251355596"},"PeriodicalIF":3.4,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating intangible costs into societal cost estimates of Alzheimer's disease. 将无形成本纳入阿尔茨海默病的社会成本估算。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-13 DOI: 10.1177/13872877251351591

Amir Abbas Tahami Monfared, Noemi Hummel, Agnieszka Kopiec, Aastha Chandak, Artak Khachatryan, Ran Gao, Raymond Zhang, Quanwu Zhang

{"title":"Integrating intangible costs into societal cost estimates of Alzheimer's disease.","authors":"Amir Abbas Tahami Monfared, Noemi Hummel, Agnieszka Kopiec, Aastha Chandak, Artak Khachatryan, Ran Gao, Raymond Zhang, Quanwu Zhang","doi":"10.1177/13872877251351591","DOIUrl":"https://doi.org/10.1177/13872877251351591","url":null,"abstract":"BackgroundAlzheimer's disease (AD) is associated with considerable economic burden, the full extent of which can be challenging to quantify from a societal perspective.ObjectiveTo estimate the total societal cost of AD in the United States by integrating direct costs, out-of-pocket expenses, indirect costs to caregivers, costs to business, and intangible/emotional costs to patients/caregivers across the disease continuum from mild cognitive impairment (MCI) to severe AD.MethodsIntangible costs were derived from a patient-caregiver survey. Other indirect costs were from a Health and Retirement Study (HRS) analysis; direct costs were from the literature. We estimated integrated societal cost per patient per month (PPPM) for MCI and AD (mild/moderate/severe). Negative binomial regression of indirect costs examined associations with severity, adjusting for baseline characteristics.ResultsIntegrated societal costs PPPM were $4176 for MCI and $7873 for AD ($6,634, $7,291, and $9287 for mild, moderate, and severe, respectively); intangible costs represented 24-32% of societal costs. Indirect costs were higher with AD versus MCI (p < 0.001); married status and nursing home residence were associated with lower indirect costs in AD.ConclusionsIntangible costs are a major driver, besides direct costs, of the integrated societal cost of MCI/AD. Societal costs are higher with more severe AD.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251351591"},"PeriodicalIF":3.4,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0